Heights Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Heights Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-156,176	Closed	-$20.3K	–	159
2024 Q4	$20.3K	Hold	156,176	–	–	0.01%	82
2024 Q3	$17.1K	Buy	+156,176	New	+$20.7K	0.01%	74

Heights Capital Management's BLACR Position: Q1 2025 in Review

Heights Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 156,176 shares — an estimated $20.3K sold.

Heights Capital Management first reported a position in BLACR in Q3 2024 and held it in 2 quarters. The position peaked at $20.3K in Q4 2024. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Heights Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Heights Capital Management sold 156,176 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $20.3K.
Heights Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q3 2024 and held it in 2 quarters.
Heights Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $20.3K in Q4 2024.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Heights Capital Management's 13F filing for Q1 2025, filed 14 May 2025.